Acrylamides

Dec 05, 2017

Phase 3 Study Evaluating IMBRUVICA® (ibrutinib) in Combination with Rituximab in Waldenström's Macroglobulinemia Met Primary Endpoint

Nov 29, 2017

Polyacrylamide Market to surpass $10.7bn by 2024: Global Market Insights, Inc.

Nov 10, 2017

Global Polyacrylamide Market Analysis & Trends 2014-2017 - Industry Forecast to 2025 - Research and Markets

Oct 26, 2017

Ibrutinib Market Analysis, Size and Forecast to 2017-2022, Share, Growth and Trends

Jun 05, 2017

Data at ASCO Show Consistent Progression-Free Survival Benefit in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients Treated with Ibrutinib, Including Those with High-Risk Disease, with Up to Four Years of Follow-Up

Jun 05, 2017

New Data Presented at ASCO 2017 Finds IMBRUVICA® (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naïve Patients